Traficet-EN (CCX282-B), an orally active inhibitor of chemokine receptor CCR9, for treatment of Crohn's disease

Traficet-EN (CCX282-B), an orally active inhibitor of chemokine receptor CCR9, for treatment of Crohn's disease

التفاصيل البيبلوغرافية
المؤلفون الرئيسيون:	Bekker, P, Velde, A, Pronk, I, Keshav, S, Hommes, D, Hanauer, S, Ungashe, S, Zheng, W, Wright, K, Schall, T
التنسيق:	Conference item
منشور في:	2007

مواد مشابهة

PROTECT-1 Maintenance Phase Study Results demonstrate efficacy of the Intestine-Specific Chemokine Receptor Antagonist CCX282-B (Traficet-EN) in Crohn's Disease
حسب: Bekker, P, وآخرون
منشور في: (2009)

Ccx282-B, an orally active inhibitor of chemokine receptor Ccr9, shows anti-inflammatory and clinical activity in the treatment of Crohn's disease
حسب: Keshav, S, وآخرون
منشور في: (2007)

PROTECT-1 Study Demonstrated Efficacy of the Intestine-Specific Chemokine Receptor Antagonist CCX282-B (Traficet-EN) in Treatment of Patients with Moderate to Severe Crohn's Disease
حسب: Keshav, S, وآخرون
منشور في: (2009)

Protect-1, a prospective randomized oral therapy evaluation of CCX282-B (Traficet-EN) in Crohn's disease trial
حسب: Bekker, P, وآخرون
منشور في: (2008)

PROTECT-1: A prospective randomized trial of CCX282-B (Traficet-EN), a novel oral therapy targeting chemokine receptor 9 in Crohn's disease
حسب: Keshav, S, وآخرون
منشور في: (2007)

Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease.
حسب: Walters, M, وآخرون
منشور في: (2010)

Traficet-EN, an Oral CCR9-Specific Antagonist, induces high levels of remission in the open-label Phase of PROTECT-1 in Crohn's Disease
حسب: Bekker, P, وآخرون
منشور في: (2008)

Traficet-EN, an oral CCR9-specific antagonist, induces high levels of remission in the open-label phase of PROTECT-1 in Crohn's disease
حسب: Bekker, P, وآخرون
منشور في: (2008)

MEDI 167-Discovery of the highly potent, selective and orally bioavailable CCR9 antagonist CCX282-B
حسب: Ungashe, S, وآخرون
منشور في: (2008)

Pharmacological inhibition of CCR9 is a novel approach in the treatment of inflammatory bowel disease
حسب: Bekker, P, وآخرون
منشور في: (2007)

Cc chemokine receptor 9 (ccr9) antagonist ameliorates experimental ileitis and colitis
حسب: Wei, Z, وآخرون
منشور في: (2005)

Expression and function of the chemokine receptor CCR7 in thyroid carcinomas.
حسب: Sancho, M, وآخرون
منشور في: (2006)

Chemokines and myeloid cell recruitment.
حسب: Greaves, D, وآخرون
منشور في: (2000)

The herpesvirus 8-encoded chemokine vMIP-II, but not the poxvirus-encoded chemokine MC148, inhibits the CCR10 receptor.
حسب: Lüttichau, H, وآخرون
منشور في: (2001)

Abduction of chemokine elements by herpesviruses
حسب: Dairaghi, D, وآخرون
منشور في: (1998)

CCR6, a CC chemokine receptor that interacts with macrophage inflammatory protein 3alpha and is highly expressed in human dendritic cells.
حسب: Greaves, D, وآخرون
منشور في: (1997)

Variants of the chemokine receptor CCR5 are associated with severe bronchiolitis caused by respiratory syncytial virus.
حسب: Hull, J, وآخرون
منشور في: (2003)

Therapeutic recommendations in HFE hemochromatosis for p.Cys282Tyr (C282Y/C282Y) homozygous genotype
حسب: Adams, P, وآخرون
منشور في: (2018)

High-Level Production, Solubilization and Purification of Synthetic Human GPCR Chemokine Receptors CCR5, CCR3, CXCR4 and CX3CR1
حسب: Xu, Zhinan, وآخرون
منشور في: (2010)

TH17 T CELLS IN ANKYLOSING SPONDYLITIS ARE POLYFUNCTIONAL AND EXPRESS HIGH LEVELS OF THE CHEMOKINE RECEPTOR CCR6
حسب: Bowness, P, وآخرون
منشور في: (2009)

Chemokine receptor CCR5 polymorphisms do not affect disease progression in hepatitis C virus infection.
حسب: Hellier, S, وآخرون
منشور في: (2000)

CCR9 antagonism: potential in the treatment of Inflammatory Bowel Disease.
حسب: Wendt, E, وآخرون
منشور في: (2015)

Highly Potent, Orally Available Anti-inflammatory Broad-Spectrum Chemokine Inhibitors
حسب: Fox, D, وآخرون
منشور في: (2009)

Activation of CCR2+ human proinflammatory monocytes by human herpesvirus-6B chemokine N-terminal peptide.
حسب: Clark, D, وآخرون
منشور في: (2013)

Copy number variation of c-c chemokine ligand 3-like 1 (CCL3L1), c-c chemokine receptor type 5 (CCR5) and CCR2 polymorphisms on the outcomes of antiretroviral therapy among Malaysian HIV patients
حسب: Mohamad Isa, Irma Izani
منشور في: (2020)

Medical management of Crohn's disease.
حسب: Cummings, JR, وآخرون
منشور في: (2008)

A novel membrane based process to isolate recombinant human chemokine receptor CCR3 produced in Escherichia coli
حسب: Liu, J, وآخرون
منشور في: (2013)

Association of genetic variants of the chemokine receptor CCR5 and its ligands, RANTES and MCP-2, with outcome of HCV infection.
حسب: Hellier, S, وآخرون
منشور في: (2003)

Mat 282- Pengiraan Kejuruteraan I
حسب: PPSM, Pusat Pengajian Sains Matematik
منشور في: (2004)

Chemokines, chemokine receptors and atherosclerosis
حسب: John, A, وآخرون
منشور في: (2005)

The duffy antigen/receptor for chemokines exists in an oligomeric form in living cells and functionally antagonizes CCR5 signaling through hetero-oligomerization.
حسب: Chakera, A, وآخرون
منشور في: (2008)

Analysis of the CC chemokine receptor 5 (CCR5)Delta 32 polymorphism in Behcet's disease (vol 31, pg 11, 2004)
حسب: Yang, X, وآخرون
منشور في: (2005)

MAT 282 - Pengiraan Kejuruteraan I - Oktober 2004
حسب: PPSM, Pusat Pengajian Sains Matematik
منشور في: (2004)

ZAE282-3 - MATERIAL SCIENCES - NOVEMBER 2008.
حسب: PPSF, Pusat Pengajian Sains Fizik
منشور في: (2008)

ZAE 282/3 - SAINS BAHAN SEPT 1997.
حسب: PPSF, Pusat Pengajian Sains Fizik
منشور في: (1997)

Crohn’s disease or Crohn’s diseases?
حسب: Arnott, IDR, وآخرون
منشور في: (2003)

Chemokines, chemokine receptors and disease : current topics in membranes /
حسب: Schwiebert, Lisa M.
منشور في: (2005)

The role of tumour-expressed CCR6 and CCR7 in breast cancer metastasis and tumour immunity
حسب: Tang, Kai Xin
منشور في: (2020)

ZAE 282E/3 - MATERIAL SCIENCE OKT 04
حسب: PPSF, Pusat Pengajian Sains Fizik
منشور في: (2004)

ZAE 282E/3 - SAINS BAHAN SEP 03.
حسب: PPSF, Pusat Pengajian Sains Fizik
منشور في: (2003)